Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study

1 September 2019 (12:40 - 13:30)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Juan Russo

University of Ottawa Heart Institute, Ottawa (Canada)

6 More presentations in this session

Presentation thumbnail

A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease

Professor T. Chao (Taichung, TW)

Presentation thumbnail

Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study

Professor D. Angiolillo (Jacksonville, US)

Abstract Slides

Presentation thumbnail

Effect of de-escalated switching dual antiplatelet therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: real-world data from a nationwide cohort study

Doctor C. Hsu (Taipei, TW)

Abstract Slides

Presentation thumbnail

Comparing treatment recommendations for the DAPT and PRECISE-DAPT scores after percutaneous coronary intervention

Doctor R. Boudreau (Ottawa, CA)

Abstract Slides

Presentation thumbnail

Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study

Professor D. Angiolillo (Jacksonville, US)

Abstract Slides

Access the full session

Session thumbnail

Evolving developments in anti-platelet therapy

The Event

ESC Congress 2019

1 September 2019 12:40 CET

You may be interested in

Webinar

Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

Congress Presentation

Antithrombotic therapy in diabetes

Congress Session

State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?